M
M.A. Jimenez-Arriero
Researcher at Complutense University of Madrid
Publications - 36
Citations - 1271
M.A. Jimenez-Arriero is an academic researcher from Complutense University of Madrid. The author has contributed to research in topics: Alcohol dependence & Naltrexone. The author has an hindex of 17, co-authored 36 publications receiving 1108 citations. Previous affiliations of M.A. Jimenez-Arriero include Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.
R. Rodriguez-Jimenez,Alexandra Bagney,C. Garcia-Navarro,Ana Aparicio,Raúl López-Antón,Marta Moreno-Ortega,M.A. Jimenez-Arriero,J.L. Santos,Antonio Lobo,Robert S. Kern,Michael F. Green,K.H. Nuechterlein,K.H. Nuechterlein,Tomás Palomo +13 more
TL;DR: Age, gender, and education had significant effects on the normative data for MCCB in China, which are comparable to those found for the original standardized English version in the U.S. and the Spanish version in Spain.
Journal ArticleDOI
Impulsivity and Sustained Attention in Pathological Gamblers: Influence of Childhood ADHD History
R. Rodriguez-Jimenez,César Ávila,M.A. Jimenez-Arriero,G. Ponce,R. Monasor,M. Jiménez,M. Aragues,Janet Hoenicka,Gabriel Rubio,Tomás Palomo +9 more
TL;DR: It is shown that patients in the PG-ADHD group exhibit a significantly lower capacity to delay gratification than those in thePG-non-ADhd and control groups, and less inhibitory control than patients inThe PG- non- ADHD group.
Journal ArticleDOI
Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment
TL;DR: There were non-significant trends for the naltrexone group to comply better with medication, to stay in the study longer, and to show greater improvement over baseline in serum GGT, though this could not explain their better outcome.
Journal ArticleDOI
Cognition and the five-factor model of the Positive and Negative Syndrome Scale in schizophrenia
Roberto Rodriguez-Jimenez,Alexandra Bagney,Laura Mezquita,Isabel Martínez-Gras,Eva-Maria Sanchez-Morla,Natalia Mesa,M.I. Ibáñez,Justo Diez-Martin,M.A. Jimenez-Arriero,Antonio Lobo,J.L. Santos,Tomás Palomo +11 more
TL;DR: Results supporting its factorial structure and reliability provide robustness to this consensus PANSS five-factor model, and indicate some usefulness of the cognitive factor in the clinical assessment of schizophrenic patients.
Journal ArticleDOI
Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone?
Gabriel Rubio,G. Ponce,R. Rodriguez-Jimenez,M.A. Jimenez-Arriero,Janet Hoenicka,Tomás Palomo +5 more
TL;DR: Patients with these features, suggesting biological vulnerability overall have poorer outcomes, but this can be reduced with NTX treatment, but the type of alcoholism should be considered before deciding on the pharmacological strategy.